Therapy of chronic graft-versus-host disease

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 2, 2008, Pages 271-279

  Arora, Mukta ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

BMT; cGVHD; chronic graft versus host disease; therapy

Indexed keywords

BECLOMETASONE; CALCINEURIN INHIBITOR; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ESTROGEN; ETANERCEPT; ETRETINATE; HYDROXYCHLOROQUINE; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PLACEBO; PREDNISONE; PSORALEN; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE;

CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS COMPLICATION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LONG TERM CARE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOTHERAPY; MORTALITY; MULTIPLE CYCLE TREATMENT; NEURITIS; NEUROTOXICITY; NEUTROPENIA; PHOTOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; PUVA; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; SCLERODERMA; SEDATION; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOPHERESIS; SALVAGE THERAPY;

EID: 44049102410     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.02.015     Document Type: Review

References (37)

1. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57 (1981) 267-276
2. Sullivan K.M., Witherspoon R.P., Storb R., et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72 (1988) 555-561
3. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100 (2002) 48-51
4. Arora M., Burns L.J., Davies S.M., et al. Chronic graft-versus-host disease: a prospective cohort study. Biology of Blood and Marrow Transplantation 9 (2003) 38-45
5. Arora M., Nagaraj S., Wagner J.E., et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biology of Blood and Marrow Transplantation 13 (2007) 1145-1152
6. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 7 (2001) 265-273
7. Koc S., Leisenring W., Flowers M.E., et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 96 (2000) 3995-3996
8. Lopez F., Parker P., Nademanee A., et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 11 (2005) 307-313
9. Baudard M., Vincent A., Moreau P., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplantation 30 (2002) 287-295
10. Busca A., Saroglia E.M., Lanino E., et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplantation 25 (2000) 1067-1071
11. Krejci M., Doubek M., Buchler T., et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Annals of Hematology 84 (2005) 681-685
12. Kim J.G., Sohn S.K., Kim D.H., et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. European Journal of Haematology 73 (2004) 56-61
13. Mookerjee B., Altomonte V., and Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplantation 24 (1999) 517-520
14. Ratanatharathorn V., Carson E., Reynolds C., et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Annals of Internal Medicine 133 (2000) 275-279
15. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 (2004) 2603-2606
16. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 20 (2006) 172-173
17. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006) 756-762
18. Couriel D.R., Saliba R., Escalon M.P., et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. British Journal of Haematology 130 (2005) 409-417
19. Jurado M., Vallejo C., Perez-Simon J.A., et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 13 (2007) 701-706
20. Johnston L.J., Brown J., Shizuru J.A., et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 11 (2005) 47-55
21. Couriel D.R., Hosing C., Saliba R., et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood 107 (2006) 3074-3080
22. Greinix H.T., Volc-Platzer B., Rabitsch W., et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92 (1998) 3098-3104
23. Apisarnthanarax N., Donato M., Korbling M., et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplantation 31 (2003) 459-465
24. Foss F.M., DiVenuti G.M., Chin K., et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplantation 35 (2005) 1187-1193
25. Kanold J., Messina C., Halle P., et al. Update on extracorporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow Transplantation 35 Suppl. 1 (2005) S69-S71
26. Akpek G., Lee S.M., Anders V., et al. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 7 (2001) 495-502
27. Jacobsohn D.A., Chen A.R., Zahurak M., et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. Journal of Clinical Oncology 25 (2007) 4255-4261
28. Willenbacher W., Basara N., Blau I.W., et al. Treatment of steroid-refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Haematology 112 (2001) 820-823
29. Chiang K.Y., Abhyankar S., Bridges K., et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73 (2002) 665-667
30. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109 (2007) 4557-4563
31. Browne P.V., Weisdorf D.J., DeFor T., et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplantation 26 (2000) 865-869
32. Parker P.M., Chao N., Nademanee A., et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 86 (1995) 3604-3609
33. Mayer J., Krejci M., Doubek M., et al. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplantation 35 (2005) 699-705
34. Lee S.J., Wegner S.A., McGarigle C.J., et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood 89 (1997) 2298-2302
35. Marcellus D.C., Altomonte V.L., Farmer E.R., et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 93 (1999) 66-70
36. Socie G., Devergie A., Cosset J.M., et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 49 (1990) 657-658
37. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397